JAK2 and myelofibrosis: Univariate logistic regression analysis showed that age, gender, interval from first diagnosis to the treatment, myelofibrosis, splenomegaly, JAK2 mutation burden, risk stratification, history of HU treatment, and history of thrombosis did not affect CHR (Figure 2).